Erythrocyte drug delivery system

International Journal of Pharmaceutical Sciences Review and Research

Volumn 8, Issue 1, 2011, Pages 124-128

  Biranwar, Yogeshkumar A ^a   Bare, Kapil R ^a   Mahajan, Vaishali R ^a   Sapate, Mangesh K ^a   Baviskar, Dheeraj T ^a  

^a Institute of Pharmaceutical Education   (India)

Author keywords

Cellular carriers; Drug delivery; Erythrocyte; Magnetic nanopartical; Resealed erythrocytes

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIRETROVIRUS AGENT; CARDIOVASCULAR AGENT; CYCLOPHOSPHAMIDE; MAGNETIC NANOPARTICLE; METAL NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; STEROID; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VITAMIN;

DIAGNOSTIC IMAGING; DRUG COATING; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; ERYTHROCYTE LIFESPAN; ERYTHROCYTE MEMBRANE; HUMAN; MAGNETIC FIELD; NANOPHARMACEUTICS; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; REVIEW; SLOW DRUG RELEASE;

EID: 79957639986     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Hamidi M, Tajerzadeh H. Carrier erythrocytes an overview. Drug Delivery, 10, 2003, 9-20.
2. Rossi L, Serafini S, Piergie F, Antonelli A, Cerasi A, Fraternale A, et al. Erythrocyte-based drug delivery. Expert Opin. Drug Deliv, 2, 2005, 311-322.
3. Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R, et al. Erythrocyte-mediated delivery of drugs, peptide sand modified oligonucleotides. Gene Ther, 11, 2002, 749-51.
4. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Advanced Drug Delivery Reviews, 58, 2006, 1471-1504.
5. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of Magnetic nanoparticles in biomedicine, Journal of Physics. D. Applied Physics, 36, 2003, R167-R181.
6. Dobson J. Magnetic nanoparticles for drug delivery. Drug Development Research, 67, 2006, 55-60.
7. Ferrari M. Cancer nanotechnology: opportunities and challenges, Nature Reviews. Cancer, 5, 2005, 161-171.
8. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. Journal of Magnetic Resonance Imaging, 25, 2007, 667-680.
9. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Investigative Radiology, 39, 2004, 619-625.
10. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Longcirculating iron oxides for MR imaging. Advanced Drug Delivery Reviews,16, 1995, 321-334.
11. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents physicochemical characteristics and applications in MR imaging. European Radiology, 11, 2001, 2319-2331.
12. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications - a review. Journal of Drug Targeting, 6, 1998, 167-174.
13. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-nodemetastases in prostate cancer. New England Journal of Medicine, 348, 2003, 2491-2499.
14. Torchilin VP. Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 58 2006, 1532-1555.
15. Zhang Y, Kohler N, Zhang MQ. Surface modification of Superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23, 2002, 1553-1561.
16. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Letters, 5, 2005, 1003-1008.
17. Winau F, Westphal O, Winau R, Ehrlich P. In search of the magic bullet Microbes and Infection, 6, 2004, 786-789.
18. Banker GS, Rhodes CT. Modern Pharmaceutics, 4th Edition. Marcel Dekker Inc. New York, 2002, 560.
19. Ropars C, Chassaigne M, Nicoulau C. Advances in the Bioscicences, Pergamon Press. Oxford, 1987, 67.
20. Lewis DA, Alpar HO. Therapeutic possibilities of drugs encapsulated in erythrocytes. Int. J. Pharm, 22, 1984, 137-46.
21. Zimmermann U. Cellular drug-carrier systems and their possible targeting, in: Goldberg (Ed.) EP, Targeted Drugs, John Wiley & Sons. New York, 1983, 153-200.
22. Jaitely V, Kanaujia P, Venkatesan N, Jain S, Vyas SP. Resealed erythrocytes: drug carrier potentials and biomedical applications. Indian Drugs, 33, 1996, 589-594.
23. Talwar N, Jain NK. Erythrocytes as carrier of primaquin preparation: characterization and evaluation. Control Release, 20, 1992, 133-142.
24. Pitt E, Lewis DA, Offord R. The use of corticosteroids encapsulated in erythrocytes in the treatment of adjuvant induced arthritis in the rat. Biochem. Pharmacol, 132 1983, 3355-3358.
25. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. Journal of Physics. D. Applied Physics, 2003, 36, R167-181.
26. Dobson J. Magnetic nanoparticles for drug delivery. Drug Development Research, 67, 2006, 55-60.
27. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature Reviews. Cancer, 5, 2005, 161-71.
28. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. Journal of Magnetic Resonance Imaging, 25, 2007, 667-680.
29. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Investigative Radiology, 39, 2004, 619-625.
30. Tartaj P, Morales MD, Veintemillas-Verdaguer S, Gonzalez-Carreno T, Serna CJ. The preparation of magnetic nanoparticles for applications in biomedicine, Journal of Physics D. Applied Physics, 36, 2003, R182-197.
31. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26, 2005, 3995-4021.
32. McNeil SE. Nanotechnology for the biologist. Journal of Leukocyte Biology, 78, 2005, 585-594.
33. Frullano L, Meade TJ. Multimodal MRI contrast agents. Journal of Biological Inorganic Chemistry, 12, 2007, 939-949.
34. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Longcirculating iron oxides for MR imaging. Advanced Drug Delivery Reviews, 16, 1995, 321-334.
35. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. European Radiology, 11, 2001, 2319-2331.
36. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications - a review. Journal of Drug Targeting, 6, 1998, 167-174.
37. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. New England Journal of Medicine, 348, 2003, 2491-2499.
38. Senyei A, Widder K, Czerlinski G. Magnetic guidance of drug-carrying microspheres. Journal Of Applied Physics, 49, 1978, 3578-3583.
39. Neuberger T, Schopf B, Hofmann H, Hofmann M, Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and Limitations of a new drug delivery system. Journal of Magnetism and Magnetic Materials, 293, 2005, 483-496.
40. Torchilin VP. Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 58 2006, 1532-1555.
41. Zhang Y, Kohler N, Zhang MQ. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23, 2002, 1553-1561.
42. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Letters, 5, 2005, 1003-1008.
43. Winau F, Westphal O, Winau R, Paul Ehrlich - In search of the magic bullet. Microbes and Infection, 6, 2004, 786-789.
44. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of Superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution Journal of Microencapsulation, 13, 1996, 245-255.
45. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, HarnischS, et al. 'Stealthiness' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids and Surfaces. Biointerfaces, 18, 2000, 301-313.
46. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews, 53, 2001, 283-318.
47. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomaterialia, 4, 2007, 413-438.
48. Nahrendorf M, Jaffer FA, Kellly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 17, 2006, 1504-1511.
49. Rader RA. What is biopharmaceutical? Part 1. Bioexecutive International 2005, 60-65.
50. Arkinson EM, Klum W. Formulation strategies for biopharmaceuticals. Ensuring success to market, drugs, 4, 2001, 557-560.